Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Eli Lilly and Company · NCT07258836

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
41
US sites recruiting
2
Study start
December 22, 2025
Record last updated
August 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

Being studied: LY4214835

Conditions: Neoplasms; Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Cohort 1
  • Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer
  • Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted therapy or immunotherapy)
  • Have at least 1 imageable tumor that is 15 millimeter (mm) or larger in the longest diameter
  • Cohort 2
  • Are overtly healthy at the Screening Visit and upon reporting to the clinic for the positron emission tomography (PET) Imaging Visit, as determined by medical evaluation including updated medical history, vital signs, physical examination, laboratory tests, and electrocardiogram (ECG)

Exclusion Criteria

  • Are pregnant or intend to become pregnant during their participation in the study
  • Are breastfeeding or intending to breastfeed during their participation in the study
  • Have a history of risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome)
  • Are actively receiving cancer therapy or are in between cycles of treatment
  • Have a marked baseline prolongation of QT/corrected QT interval (QTc) interval (for example, repeated demonstration of a QTc interval greater than (>) 450 millisecond (ms)

Recruiting US locations

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
A Study of [18F]LY4214835 in Healthy Volunteers and Participants… (NCT07258836) | Bored Studies